Abstract
Evidence related to reinduction of first-line therapy after maintenance in metastatic colorectal cancer (mCRC) patients remains insufficient. Only about 40% of our patients receive second-line therapy, raising concerns about the efficacy of this treatment plan. We hypothesized that prolongation of first-line therapy may affect patient's probability of receiving second-line therapy and therefore, we aimed to investigate how reinduction and prolongation of the first-line therapy affects overall survival (OS).
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call